Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study
Therapeutic Advances in Infectious Disease · 2026-08 · 13
DOI: 10.1177/20499361261464359 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 04.08.2026. Verfasst von Masaya Yamato und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shionogi.
Abstract (Originalsprache)
Background
Immunocompromised patients have a risk of severe COVID-19.
Objectives
To describe the outcomes of ensitrelvir in hospitalized immunocompromised patients with COVID-19, with remdesivir as a reference.
Design
Single-center retrospective cohort study.
Methods
We analyzed patients with moderate/severe immunodeficiency who received ensitrelvir or remdesivir as initial therapy. The primary outcome was 28-day all-cause mortality; secondary outcomes were time to discharge and viral clearance. Exploratory analyses used inverse probability of treatment weighting (IPTW) based on propensity scores and Cox proportional-hazards models.
Results
Among 56 patients (22 ensitrelvir; 34 remdesivir), 28-day mortality was 4.5% versus 8.8%, respectively. Time to discharge and viral clearance were similar. IPTW-adjusted 28-day mortality was 4.2% with ensitrelvir and 10.7% with remdesivir (hazard ratio 0.39; 95% CI 0.04–3.64).
Conclusion
In this small, single-center exploratory cohort, ensitrelvir was associated with low mortality, although comparison with remdesivir should be interpreted cautiously given treatment selection, treatment switching, and limited sample size.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan.
- Medical Affairs Department, Shionogi & Co., Ltd., Grand Green Osaka South Building Park Tower, 5-54 Ofuka-Cho, Kita-Ku, Osaka 530-0011, Japan.
- Data Science Department, Shionogi & Co., Ltd., Osaka, Japan.
- Pharmaceutical Department, Rinku General Medical Center, Izumisano, Japan.
- Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan.
ORCID-Profile: Masahiro Kinoshita
Förderung
- Shionogi
Zitieren
APA
Yamato, M., Kinoshita, M., Yoshida, Y., Yamamoto, Y., Izuhara, R., & Sonoyama, T. (2026). Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study. Therapeutic Advances in Infectious Disease, 13. https://doi.org/10.1177/20499361261464359
Vancouver
Yamato M, Kinoshita M, Yoshida Y, Yamamoto Y, Izuhara R, Sonoyama T. Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study. Therapeutic Advances in Infectious Disease. 2026;13. doi:10.1177/20499361261464359
BibTeX
@article{Yamato2026,
author = {Yamato, Masaya and Kinoshita, Masahiro and Yoshida, Yuki and Yamamoto, Yudai and Izuhara, Rie and Sonoyama, Takuhiro},
title = {Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study},
journal = {Therapeutic Advances in Infectious Disease},
year = {2026},
volume = {13},
doi = {10.1177/20499361261464359}
}
EUVIMED